March 26, 2025 03:26 PM EDT

FDA critiques Taiho Oncology's 'misleading' promotional website for bile duct cancer drug

Zachary Brennan

Senior Editor

The FDA is taking issue with a promotional website from Taiho Oncology, alleging it misleadingly describes the benefits of its bile duct cancer drug Lytgobi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA critiques Taiho Oncology's 'misleading' promotional website for bile duct cancer drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

FDA approves Sanofi's RNAi drug for hemophilia A and B

FDA cri­tiques Tai­ho On­col­o­gy's 'mis­lead­ing' pro­mo­tion­al web­site for bile duct can­cer drug

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B

FDA critiques Taiho Oncology's 'misleading' promotional website for bile duct cancer drug

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

FDA approves Sanofi's RNAi drug for hemophilia A and B